JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus

Summary

The trial will evaluate pharmacodynamics，pharmacokinetics，safety，and efficacy of JMKX000189 versus placebo in participants with moderately to severely active systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment.

Timeline

Start

2023-09-21

Primary completion

2025-05

Completion

2025-12

Drugs

Indications